References
- Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(3): 456–462. doi:10.1016/j.jcf.2022.01.009
- Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, et al. Triple therapy for cystic fibrosis Phe508del–gating and –residual function genotypes. New England Journal of Medicine. 2021;385(9): 815–825. doi:10.1056/NEJMoa2100665
- Mall MA, Wainwright CE, Legg J, Chilvers M, Gartner S, Dittrich AM, et al. Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study. European Respiratory Journal. 2025;66(1): 2402435. doi:10.1183/13993003.02435-2024
- Wang Y, Ma B, Li W, Li P. Efficacy and safety of triple combination cystic fibrosis transmembrane conductance regulator modulators in patients with cystic fibrosis: a meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2022;13: 863280. doi:10.3389/fphar.2022.863280
- Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A. A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. Cureus. 2021;13(7): e16144. doi:10.7759/cureus.16144
- Salvatore D, Pepe A. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: a review of registry-based evidence. Journal of Clinical Medicine. 2025;14(11): 3978. doi:10.3390/jcm14113978
- Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. New England Journal of Medicine. 2019;381(19): 1809–1819. doi:10.1056/nejmoa1908639
- Goralski JL, Hoppe JE, Mall MA, McColley SA, McKone E, Ramsey B, et al. Phase 3 open-label clinical trial of elexacaftor/tezacaftor/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele. American Journal of Respiratory and Critical Care Medicine. 2023;208(1): 59–67. doi:10.1164/rccm.202301-00840C
- Dettmer S, Weinheimer O, Sauer-Heilborn A, Lammers O, Wielpütz MO, Fuge J, et al. Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study. Frontiers in Pharmacology. 2023;14: 1245885. doi:10.3389/fphar.2023.1245885
- Hernández-Muñiz S, Caballero P, Peláez A, Solís-García M, de Benavides C, Collada J, et al. Evolution of lung disease studied by computed tomography in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Journal of Imaging. 2025;11(4): 124. doi:10.3390/jimaging11040124
- Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991;179(3): 783–788. doi:10.1148/radiology.179.3.2027992
- Zubair M, Schmidt H, Sharma G. Sweat testing. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated Feb 17, 2025. PMID: 31613508.
- Gokdemir Y, Karadag BT. Sweat testing and recent advances. Frontiers in Pediatrics. 2021;9: 649904. doi:10.3389/fped.2021.649904
- Earnest A, Salimi F, Wainwright CE, Bell SC, Ruseckaite R, Ranger T, et al. Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry. Scientific Reports. 2020;10(1): 17421. doi:10.1038/s41598-020-74502-1
- de Aquino CSB, Rodrigues JC, da Silva-Filho LVRF. Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline. Jornal Brasileiro de Pneumologia: Publicacao Oficial da Sociedade Brasileira de Pneumologia E Tisilogia. 2022;48(3): e20210237. doi:10.36416/1806-3756/e20210237
- Streibel C, Willers CC, Pusterla O, Bauman G, Stranzinger E, Brabandt B, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI. Journal of Cystic Fibrosis. 2023;22(4): 615–622. doi:10.1016/j.jcf.2022.12.012
- Dawood SN, Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, et al. Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review. Cureus. 2022;14(9): e29359. doi:10.7759/cureus.29359
- Martins GDS, Rambo C, Spessatto G, Saab MM, João BHD, Fajardo AD, et al. Efficacy and safety of using Elexacaftor/Tezacaftor/Ivacaftor in the treatment of children with cystic fibrosis: real-world evidence from Brazil. Jornal de Pediatria. 2025;101(5): 101420. doi:10.1016/j.jped.2025.05.007
- Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. New England Journal of Medicine. 1992;326(18):1187–1191. doi:10.1056/NEJM199204303261801